XTALPI (02228) experienced a surge of over 8% in late trading. By the time of writing, the stock had risen 8.14% to HK$9.17, with a turnover of HK$537 million. The catalyst for the movement was an announcement made on April 27 by XTALPI's CEO, Ma Jian, at the 2026 Guangdong Artificial Intelligence Application Matchmaking Conference. He revealed that SIGX2649, a pan-TEAD inhibitor developed by Signet Sciences, a company incubated by XTALPI's AI-driven autonomous experimentation platform, has completed its preclinical studies. Applications for an Investigational New Drug (IND) status will be submitted concurrently to regulatory authorities in both China and the United States. The related research findings are also scheduled to be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. SIGX2649 is reported to be a potential first-in-class and best-in-class pan-TEAD inhibitor, targeting a broad market for solid tumor treatments. As TEAD inhibitors target the core of the HIPPO signaling pathway, preclinical data indicates that SIGX2649 effectively inhibits all four TEAD subtypes, demonstrating superior anti-tumor activity, reduced renal toxicity, and significant potential for combination therapies. Currently, there are no approved drugs globally that target this specific mechanism.